These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy. Smith NR; Baker D; Farren M; Pommier A; Swann R; Wang X; Mistry S; McDaid K; Kendrew J; Womack C; Wedge SR; Barry ST Clin Cancer Res; 2013 Dec; 19(24):6943-56. PubMed ID: 24030704 [TBL] [Abstract][Full Text] [Related]
33. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Greenberg JI; Cheresh DA Expert Opin Biol Ther; 2009 Nov; 9(11):1347-56. PubMed ID: 19761418 [TBL] [Abstract][Full Text] [Related]
34. Antiangiogenic therapy: Markers of response, "normalization" and resistance. El Alaoui-Lasmaili K; Faivre B Crit Rev Oncol Hematol; 2018 Aug; 128():118-129. PubMed ID: 29958627 [TBL] [Abstract][Full Text] [Related]
35. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?]. Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849 [TBL] [Abstract][Full Text] [Related]
36. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Dickson PV; Hamner JB; Sims TL; Fraga CH; Ng CY; Rajasekeran S; Hagedorn NL; McCarville MB; Stewart CF; Davidoff AM Clin Cancer Res; 2007 Jul; 13(13):3942-50. PubMed ID: 17606728 [TBL] [Abstract][Full Text] [Related]
37. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Viallard C; Larrivée B Angiogenesis; 2017 Nov; 20(4):409-426. PubMed ID: 28660302 [TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Niu G; Chen X Curr Drug Targets; 2010 Aug; 11(8):1000-17. PubMed ID: 20426765 [TBL] [Abstract][Full Text] [Related]
39. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab. Vangestel C; Van de Wiele C; Van Damme N; Staelens S; Pauwels P; Reutelingsperger CP; Peeters M J Nucl Med; 2011 Nov; 52(11):1786-94. PubMed ID: 22045708 [TBL] [Abstract][Full Text] [Related]
40. Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions. Goldberg RM; Hurwitz HI; Fuchs CS Clin Adv Hematol Oncol; 2005 Dec; 3(12):1-10; quiz 11. PubMed ID: 16555433 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]